I. Company Profile:

Tibet Nuodikang Pharmaceutical Co., Ltd. was established in the Tibet Autonomous Region on July 14, 1999, and its shares started trading on the Shanghai Stock Exchange on July 21, 1999. It is the first high-tech pharmaceutical listed enterprise in the Tibet Autonomous Region. The stock name is "Tibet Pharmaceutical Industry", and the stock code is 600211. Since its establishment, the company has been recognized as a national-level high-tech enterprise and a key leading enterprise in agricultural industrialization. The company's graphic trademark (auspicious cloud pattern) has been recognized as a well-known trademark in China by the State Administration for Industry and Commerce. The company has won many honors, including the First Prize of the Science and Technology Progress Award of the China Association of Traditional Chinese Medicine, the Reputation List of Chinese Listed Companies —— The Most Growth-oriented Listed Company in the Biomedical Field, the Golden Bull Most Investment-worthy Award, and the First Prize of the Sichuan Provincial Science and Technology Progress Award.

Adhering to the concept of "Science Achieves Health, and Health Achieves the Future", after more than two decades of development, the company has grown into a modern pharmaceutical enterprise integrating research and development, production, and sales. The company has established an enterprise technology center; four drug production bases for biological products, Tibetan medicine products, and traditional Chinese medicine products that meet GMP standards; one planting base for traditional Chinese and Tibetan medicinal materials that meets GAP standards; and one vaccine production base. Currently, the company has nine subsidiaries in Tibet, Sichuan, Shanghai, Hong Kong and other places, including Sichuan Nuodikang Weiguang Pharmaceutical Co., Ltd., Chengdu Nuodikang Biopharmaceutical Co., Ltd., Tibet Nuodikang Tibetan Medicinal Materials Development Co., Ltd., Tibet Nuodikang Pharmaceutical Co., Ltd., Hong Kong Topregi Pharmaceutical Co., Ltd., Tibet Yangdao Big Health Life Science Co., Ltd., Shanghai Xinhuo Biotechnology Co., Ltd., Tibet Nuodikang Technology Development Co., Ltd., and Tibet Nuodikang Biomedical Sales Co., Ltd.

The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical pharmaceuticals; they involve fields such as cardiovascular and cerebrovascular diseases, liver and gallbladder diseases, orthopedic pain relief, rheumatism, and cold medications. The core products include "Xinhuosu", the first class I new national biological product in China for the treatment of acute heart failure independently developed by the company, "Nuodikang" made from the Tibetan medicinal material Rhodiola rosea as the raw material, and "Imdur", a first-line drug for cardiovascular diseases internationally. In addition, the company also has excellent national traditional Chinese medicine varieties such as "Xueshan Jinluohan Pain-relieving Film Coating", "Shiwei Dida Capsules", and "Xiao'er Shuangqing Granules".

II. Corporate Background:

Establishment and Listing: It was established on July 14, 1999, and was set up through share offerings by five shareholders, namely Tibet Huaxi Pharmaceutical Group Co., Ltd., Tibetan Medicine Factory of Tibet Autonomous Region, Science and Technology Development Center of Tibet Autonomous Region, Tibet Kelong Building Materials Co., Ltd., and Tibet Keguang Solar Engineering Technology Co., Ltd. It was listed on the Shanghai Stock Exchange on July 21, 1999, with the stock name "Tibet Pharmaceutical Industry" and the stock code 600211.

Development History: From 1999 to 2005 was the entrepreneurial construction period. The company completed the layout construction of scientific research and production subsidiary bases and the construction of the first round of major technological transformation projects. All production units passed GMP certification. Multiple subsidiaries were established and completed GSP transformation and certification. The company obtained a number of titles, and the product sales revenue was nearly 100 million yuan. From 2006 to 2014 was the consolidation and development period. The company obtained special qualifications such as the National-recognized Enterprise Technology Center. The Xinhuosu project was included in the national key special support development plan. The company carried out technological transformation in accordance with the new GMP standards. Nuodikang Capsules were included in the National Essential Medicine List, and the average annual sales revenue exceeded 1 billion yuan. Since 2014 has been the leapfrog development period. The company adjusted the product operation mechanism, acquired assets related to Imdur to expand global business. Xinhuosu was included in the medical insurance catalog, and several subsidiaries were established to expand business areas.

Enterprise Nature and Honors: It is a national-level high-tech enterprise and a key leading enterprise in agricultural industrialization. The company's graphic trademark (auspicious cloud pattern) is a well-known trademark in China. It has also won many honors such as the First Prize of the Science and Technology Progress Award of the China Association of Traditional Chinese Medicine, the Golden Bull Most Investment-worthy Award, and the First Prize of the Sichuan Provincial Science and Technology Progress Award.

Shareholder Composition: The main initiator is Tibet Huaxi Pharmaceutical Group Co., Ltd., and the other four initiators are Tibetan Medicine Factory of Tibet Autonomous Region, Science and Technology Development Center of Tibet Autonomous Region, Tibet Kelong Building Materials Co., Ltd., and Tibet Keguang Solar Engineering Technology Co., Ltd. At the end of 2014, Shenzhen Kangzhe Pharmaceutical took control and formed a strategic alliance with Tibet Huaxi Pharmaceutical Group.

Business Scope and Products: The business covers drug wholesale, import and export, and the operation of Class III medical devices, etc. The products include biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical pharmaceuticals, involving fields such as cardiovascular and cerebrovascular diseases, liver and gallbladder diseases, orthopedic pain relief, rheumatism, and cold medications. The core products include Xinhuosu, Nuodikang, Imdur, etc.

III. Business Scope:

The business scope of Guoneng Rixin Technology Co., Ltd. mainly includes the following aspects:

Energy Data Management: Based on the accumulated prediction data and experience of serving more than a thousand power stations, and by using core technologies such as big data technology, supercomputing, and AI, it provides customers with system solutions such as multi-dimensional and refined prediction, evaluation, and data governance.

Smart Power Stations: Based on the single-station needs of wind and photovoltaic power stations, it helps customers solve system services and supporting solutions such as grid connection control, monitoring and operation and maintenance, centralized operation management of power stations, and comprehensive energy control from the power generation side.

Smart Grids: Based on the needs of the power grid side, it provides system solutions such as energy resource planning, new energy carrying capacity assessment, energy consumption, and power grid operation management for the State Grid Corporation of China and China Southern Power Grid in terms of new energy management.

Power Trading: Based on the trading needs of new energy wind and photovoltaic power, it uses prediction data and technologies to assist in trading decisions and provides trading assistance services for spot and medium- and long-term power generation.

In addition, the company has also actively extended and expanded related innovative businesses such as smart energy storage, virtual power plants, and comprehensive energy services around its core business, forming a business matrix with significant growth potential.

(1) Drug-related Business:

1, Production and Sales: The products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical pharmaceuticals, involving fields such as cardiovascular and cerebrovascular diseases, liver and gallbladder diseases, orthopedic pain relief, rheumatism, and cold medications. The core products are Xinhuosu, Nuodikang, Imdur, and it also has excellent national traditional Chinese medicine varieties such as Xueshan Jinluohan Pain-relieving Film Coating, Shiwei Dida Capsules, and Xiao'er Shuangqing Granules.

2, Drug Import and Export: Carry out drug import and export business.

(2) Medical Device Business: It hold shares Beijing Amate Medical Device Co., Ltd. and established Shanghai Xinhuo Biotechnology Co., Ltd. to expand the medical device product line, involving the sales of Class I medical devices, the sales of Class II medical devices, and the operation of Class III medical devices, etc.

(3) Big Health Business: Established Tibet Yangdao Big Health Life Science Co., Ltd., launched big health products such as Yuanyang Rhodiola Rosea Moisturizing Essence Liquid, and carried out health consultation services, etc.

IV. Case Studies:

(1) Modern Tibetan Medicine — Nuodikang Capsules

(2) Modern Traditional Chinese Medicine — Xiao'er Shuangqing Granules

(3) Biopharmaceuticals — Recombinant Human Brain Natriuretic Peptide for Injection

(4) Chemical Drugs — Isosorbide Mononitrate Sustained-release Tablets

(5) Big Health — Yuanyang Rhodiola Rosea Moisturizing Essence Liquid

V. Honors & Accolades:

(1) High-tech Enterprise in 2023

(2) The First Batch of High-quality Tibetan Medicines in the Tibet Autonomous Region

(3) Model in 2023

(4) China Patent Excellence Award

(5) First Prize of the Sichuan Provincial Science and Technology Progress Award